Clinical Trial Update: High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating high-dose Interferon alfa plus Interleukin-2 in patients with metastatic kidney cancer and melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Melanoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Hoag Memorial Hospital Presbyterian | Conditions: Kidney Cancer, Melanoma (Skin) | Phase 2 | Status: COMPLETED